Palmeux (Paliperidone Palmitate)

Paliperidone palmitate is a pro‑drug that releases paliperidone gradually after intramuscular injection. Paliperidone blocks dopamine D2 and serotonin 5‑HT2A receptors, helping to normalise neurotransmitter activity in brain pathways that underlie psychotic symptoms and mood instability.

The dose of Palmeux is determined by the prescribing clinician based on the patient’s clinical status, prior response to oral therapy, and tolerability. Dosing regimens are individualised and should follow the product’s prescribing information.

Palmeux should only be used during pregnancy or lactation if the potential benefit justifies the potential risk to the fetus or infant. Clinicians are advised to discuss risks and benefits with the patient and consider alternative treatments when appropriate.

To order Palmeux, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details and necessary import documentation.

Palmeux offers a long‑acting injectable option that provides stable plasma levels over weeks, reducing the need for daily oral dosing and improving adherence compared with oral antipsychotics. It shares a similar efficacy profile with other atypical antipsychotics but differs in its dosing interval and injection‑site considerations.

Palmeux should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain stability.

Palmeux is administered as an intramuscular injection, typically into the deltoid or gluteal muscle, by a qualified healthcare professional. The injection schedule is based on the prescribed dosing regimen, which may involve an initial loading phase followed by maintenance doses.

Serious risks include neuroleptic malignant syndrome, tardive dyskinesia, severe hypotension, seizures, elevated prolactin levels causing galactorrhoea, myocardial infarction and severe allergic reactions. Patients should be monitored closely for any signs of these conditions.

Palmeux is contraindicated in patients with known hypersensitivity to paliperidone, paliperidone palmitate or any excipients in the formulation. Caution is also advised for individuals with uncontrolled cardiovascular disease, severe hepatic impairment, or a history of neuroleptic malignant syndrome.